Document is current
Any future updates will be listed below
-
Authors
Peng, Xuejun Victor
Klingensmith, Georgeanna
Hsia, Daniel S.
Xie, Yunlong
Czerniak, Richard
Tamborlane, William V.
Shah, Amy S.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02856113 at ClinicalTrials.govDocuments that mention this clinical trial
A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus
https://doi.org/10.1007/s13300-025-01700-3
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals Company Limited, Cambridge, MA, USA
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 22 January 2025
First Online: 4 March 2025
Declarations
:
: Xuejun Victor Peng, Richard Czerniak, and Yunlong Xie are employees of Takeda Pharmaceuticals Company Limited, Cambridge, MA, USA. Georgeanna Klingensmith, Daniel S. Hsia, William V. Tamborlane, and Amy S. Shah have no conflicts of interests to declare. The new affiliation of Daniel S. Hsia is Emory University, Department of Pediatrics, Division of Endocrinology and Children's Healthcare of Atlanta, Atlanta, GA, USA. Georgeanna Klingensmith is now retired from Barbara Davis Center and Department of Pediatrics, University of Colorado, Aurora, CO, USA.
: The study (ClinicalTrials.gov: NCT02856113; EudraCT: 2015-000208-25) was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Guidelines for Good Clinical Practice, and all applicable laws and regulations. The study was approved by the appropriate regulatory agencies and institutional review boards (IRBs)/ethics committees (IRB Protocol ID: 2000022953). Written informed consent was provided by the parents or legal guardians, and the children/adolescents provided assent to participate in the study.
